From Wall Street Journal:

Novartis is on the verge of acquiring Cytokinetics and its valuable heart drug, in the midst of a trend of pharmaceutical companies buying up biotechs for new drugs. The Swiss drug company’s potential purchase of Cytokinetics, valued at $9 billion, may be finalized this week. Other potential suitors or the lack of a deal could change the outcome. This news is in line with the ongoing trend of pharmaceutical companies seeking to bolster their pipelines with new acquisitions.



Read more: Novartis in Advanced Talks to Buy Cytokinetics